Drug recall · July 6, 2022
Tegsedi recall
Why: Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01
- Lots / codes
Lots: 028C21AB, 028C21AC, Exp. 05/2025
- Quantity
- 450 cartons
- Company
- Akcea Therapeutics, Inc., Carlsbad, CA
- Distribution
- KY, USA
- Initiated
- May 23, 2022 · Voluntary: Firm initiated
- Classified
- June 27, 2022
- Reported
- July 6, 2022
- Ended
- April 4, 2023
- How notified
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.